Additionally, the melanoma patients presenting the most severe immune-related adverse events (diarrhea, nausea, pruritic rash, amongst others) due to ipilimumab treatment, demonstrate the highest CTLA4 mRNA fold change Supplementary Table 1. This evidence concerns the gene CTLA4 and melanoma.